Overview

  • Product nameAnti-CBL (phospho Y731) antibody [EP973Y]
    See all CBL primary antibodies
  • Description
    Rabbit monoclonal [EP973Y] to CBL (phospho Y731)
  • Specificityab52855 detects CBL phosphorylated on Tyrosine 731.
  • Tested applicationsSuitable for: WB, IPmore details
    Unsuitable for: Flow Cyt,ICC or IHC-P
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    A synthetic phospho-peptide corresponding to residues surrounding Tyr731 of human CBL.

  • Positive control
    • Raji cell lysates.
  • General notes

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

Applications

Our Abpromise guarantee covers the use of ab52855 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/2000. Detects a band of approximately 120 kDa (predicted molecular weight: 100 kDa).
IP 1/50.
  • Application notesIs unsuitable for Flow Cyt,ICC or IHC-P.
  • Target

    • FunctionParticipates in signal transduction in hematopoietic cells. Adapter protein that functions as a negative regulator of many signaling pathways that start from receptors at the cell surface. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including PDGFA, EGF and CSF1, and terminates signaling.
    • PathwayProtein modification; protein ubiquitination.
    • Involvement in diseaseDefects in CBL are the cause of Noonan syndrome-like disorder (NSL) [MIM:613563]. NSL is a syndrome characterized by a phenotype reminiscent of Noonan syndrome. Clinical features are highly variable, including facial dysmorphism, short neck, developmental delay, hyperextensible joints and thorax abnormalities with widely spaced nipples. The facial features consist of triangular face with hypertelorism, large low-set ears, ptosis, and flat nasal bridge. Some patients manifest cardiac defects.
    • Sequence similaritiesContains 1 Cbl-PTB (Cbl-type phosphotyrosine-binding) domain.
      Contains 1 RING-type zinc finger.
      Contains 1 UBA domain.
    • DomainThe RING-type zinc finger domain mediates binding to an E2 ubiquitin-conjugating enzyme.
      The N-terminus is composed of the phosphotyrosine binding (PTB) domain, a short linker region and the RING-type zinc finger. The PTB domain, which is also called TKB (tyrosine kinase binding) domain, is composed of three different subdomains: a four-helix bundle (4H), a calcium-binding EF hand and a divergent SH2 domain.
    • Post-translational
      modifications
      Phosphorylated on tyrosine residues by EGFR, SYK, FYN and ZAP70 (By similarity). Phosphorylated on tyrosine residues by INSR.
    • Cellular localizationCytoplasm.
    • Information by UniProt
    • Database links
    • Alternative names
      • 4732447J05Rik antibody
      • C CBL antibody
      • Cas Br M (murine) ecotropic retroviral transforming sequence antibody
      • Casitas B lineage lymphoma proto oncogene antibody
      • Casitas B-lineage lymphoma proto-oncogene antibody
      • CBL 2 antibody
      • cbl antibody
      • CBL_HUMAN antibody
      • CBL2 antibody
      • E3 ubiquitin protein ligase CBL antibody
      • E3 ubiquitin-protein ligase CBL antibody
      • Oncogene CBL2 antibody
      • Proto oncogene c CBL antibody
      • Proto-oncogene c-CBL antibody
      • RGD1561386 antibody
      • RING finger protein 55 antibody
      • RNF55 antibody
      • Signal transduction protein CBL antibody
      see all

    Anti-CBL (phospho Y731) antibody [EP973Y] images

    • All lanes : Anti-CBL (phospho Y731) antibody [EP973Y] (ab52855) at 1/2000 dilution

      Lane 1 : Raji cell lysate untreated
      Lane 2 : Raji cell lysate treated with pervanadate

      Lysates/proteins at 10 µg per lane.

      Secondary
      Goat anti-rabbit HRP at 1/2000 dilution

      Predicted band size : 100 kDa
      Observed band size : 120 kDa (why is the actual band size different from the predicted?)

    References for Anti-CBL (phospho Y731) antibody [EP973Y] (ab52855)

    This product has been referenced in:
    • Wang D  et al. Tespa1 is involved in late thymocyte development through the regulation of TCR-mediated signaling. Nat Immunol 13:560-8 (2012). Read more (PubMed: 22561606) »
    • Lee JO  et al. Metformin regulates glucose transporter 4 (GLUT4) translocation through AMP-activated protein kinase (AMPK)-mediated Cbl/CAP signaling in 3T3-L1 preadipocyte cells. J Biol Chem 287:44121-9 (2012). WB . Read more (PubMed: 23135276) »

    See all 3 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab52855.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"